Exact Sciences Corporation (EXAS)

The past six months have seen several events impacting EXACT Sciences Corp.'s stock price. The company announced better-than-expected revenue in Q2 2025 and presented its strategic vision at the Baird Global Healthcare Conference in September 2025. EXACT Sciences reported strong Q3 results, but the stock experienced a significant drop following the Q3 earnings announcement. Reports of Abbott Laboratories nearing a deal to acquire EXACT Sciences caused the stock to surge, and Abbott Laboratories agreed to acquire EXACT Sciences for approximately $21 billion in equity value. EXACT Sciences applauded the passage of federal legislation establishing a Medicare coverage pathway for multi-cancer early detection tests. The company announced that its Oncotype DX Breast Recurrence Score test had been used by over two million patients worldwide.

There is an indication of demand seasonality for EXACT Sciences Corp.'s products. Typical seasonality was mentioned as one of the key reasons for accelerated growth in the second half of 2024 for Cologuard.

EXACT Sciences Corp. is a molecular diagnostics company focused on early cancer detection and prevention. Its products include Cologuard, a non-invasive stool-based DNA screening test for colorectal cancer, and the Oncotype DX Suite, a collection of tissue-based genomic tests for precision oncology. The company also offers OncoExTra, a liquid-based comprehensive genomic profiling test, Riskguard Test, a hereditary cancer test, Oncoguard Liver, a blood-based screening test for liver cancer, and Oncotype DX AR-V7 Nucleus Detect, a liquid biopsy assay for detecting acquired resistance to AR-targeted therapy in prostate cancer. The company has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multi-cancer screening.

EXACT Sciences Corp. provides its cancer screening and diagnostic test products in the United States and internationally. While some products are primarily available in the US, the Oncotype DX tests are available in over 90 countries.

EXACT Sciences Corp. has maintained a strong brand reputation, driven by its advancements in cancer diagnostics and positive clinical outcomes. The Oncotype DX Breast Recurrence Score test surpassed 2 million patients worldwide, highlighting its role as a global standard of care. The launch of CancerGuard and the strong demand for Cologuard have positively impacted the company's reputation. Breakthrough results from the ALTUS study, demonstrating the Oncoguard Liver blood test's superior early detection of liver cancer, further enhanced its standing. The company's commitment to cancer eradication contributes to a positive public image. EXACT Sciences has been recognized as a certified Great Place To Work for seven years running. The agreement for Abbott Laboratories to acquire EXACT Sciences can be seen as a validation of EXACT Sciences' strong position and innovative diagnostic assets.

EXACT Sciences Corp.'s ownership is a mix of institutional, retail, and individual investors. Approximately 49.99% of the company's stock is owned by Institutional Investors, 1.20% by Insiders, and 48.80% by Public Companies and Individual Investors. Major institutional owners include Fmr Llc, Vanguard Group Inc., Capital World Investors, BlackRock, Inc., Wellington Management Group Llp, State Street Corp, JPMorgan Investment Management, Inc., and T. Rowe Price Investment Management, Inc.